These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30926526)

  • 21. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa.
    Liu Z; Lin Y; Lu Q; Li F; Yu J; Wang Z; He Y; Song C
    Infection; 2017 Feb; 45(1):23-31. PubMed ID: 27189338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo.
    Singh N; Romero M; Travanut A; Monteiro PF; Jordana-Lluch E; Hardie KR; Williams P; Alexander MR; Alexander C
    Biomater Sci; 2019 Sep; 7(10):4099-4111. PubMed ID: 31355397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterizations of the viability and gene expression of dispersal cells from Pseudomonas aeruginosa biofilms released by alginate lyase and tobramycin.
    Daboor SM; Raudonis R; Cheng Z
    PLoS One; 2021; 16(10):e0258950. PubMed ID: 34695148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach.
    Günday Türeli N; Türeli AE; Schneider M
    Int J Pharm; 2016 Dec; 515(1-2):343-351. PubMed ID: 27744035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and characterization of chitosan oligosaccharide-capped gold nanoparticles as an effective antibiofilm drug against the Pseudomonas aeruginosa PAO1.
    Khan F; Lee JW; Manivasagan P; Pham DTN; Oh J; Kim YM
    Microb Pathog; 2019 Oct; 135():103623. PubMed ID: 31325574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
    Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M
    J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polydopamine-Mediated Immobilization of Alginate Lyase to Prevent P. aeruginosa Adhesion.
    Alves D; Sileika T; Messersmith PB; Pereira MO
    Macromol Biosci; 2016 Sep; 16(9):1301-10. PubMed ID: 27198822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiofilm Potential of Silver Sulfadiazine-Loaded Nanoparticle Formulations: A Study on the Effect of DNase-I on Microbial Biofilm and Wound Healing Activity.
    Patel KK; Surekha DB; Tripathi M; Anjum MM; Muthu MS; Tilak R; Agrawal AK; Singh S
    Mol Pharm; 2019 Sep; 16(9):3916-3925. PubMed ID: 31318574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psl Produced by Mucoid
    Jones CJ; Wozniak DJ
    mBio; 2017 Jun; 8(3):. PubMed ID: 28634241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.
    Torres BGS; Helfer VE; Bernardes PM; Macedo AJ; Nielsen EI; Friberg LE; Dalla Costa T
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biofilm inhibitory effect of alginate lyases on mucoid
    Mahajan S; Sunsunwal S; Gautam V; Singh M; Ramya TNC
    Biochem Biophys Rep; 2021 Jul; 26():101028. PubMed ID: 34095554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
    Pastor M; Moreno-Sastre M; Esquisabel A; Sans E; Viñas M; Bachiller D; Asensio VJ; Pozo AD; Gainza E; Pedraz JL
    Int J Pharm; 2014 Dec; 477(1-2):485-94. PubMed ID: 25445528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of alginate-producing Pseudomonas aeruginosa on alveolar macrophage apoptotic cell clearance.
    McCaslin CA; Petrusca DN; Poirier C; Serban KA; Anderson GG; Petrache I
    J Cyst Fibros; 2015 Jan; 14(1):70-77. PubMed ID: 25027418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
    Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
    Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Sardo C; Di Domenico EG; Porsio B; De Rocco D; Santucci R; Ascenzioni F; Giammona G; Cavallaro G
    Int J Pharm; 2019 May; 563():347-357. PubMed ID: 30935918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization.
    Islan GA; Tornello PC; Abraham GA; Duran N; Castro GR
    Colloids Surf B Biointerfaces; 2016 Jul; 143():168-176. PubMed ID: 27003467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.